Chemistry:Firsocostat
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C28H31N3O8S | |
| Molar mass | 569.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Firsocostat is an acetyl-CoA carboxylase inhibitor that functions in the liver. Its original designation was GS-0976.[1] It was discovered by Nimbus Therapeutics.[2] The drug is under development by Gilead as a treatment for non-alcoholic fatty liver disease.[3]
References
- ↑ Alkhouri, Naim; Lawitz, Eric; Noureddin, Mazen; DeFronzo, Ralph; Shulman, Gerald I. (1 February 2020). "GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)". Expert Opinion on Investigational Drugs 29 (2): 135–141. doi:10.1080/13543784.2020.1668374. PMID 31519114.
- ↑ Harriman, Geraldine; Greenwood, Jeremy; Bhat, Sathesh; Huang, Xinyi; Wang, Ruiying; Paul, Debamita; Tong, Liang; Saha, Asish K. et al. (29 March 2016). "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats". Proceedings of the National Academy of Sciences 113 (13): E1796-805. doi:10.1073/pnas.1520686113. PMID 26976583. Bibcode: 2016PNAS..113E1796H.
- ↑ Alkhouri, Naim (1 February 2020). "NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges". Expert Opinion on Investigational Drugs 29 (2): 87. doi:10.1080/13543784.2020.1721169. PMID 31984804.
 |  |
